847615-01-4 Usage
Uses
Used in Medicinal Chemistry:
4-Aminomethyl-4-(4-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of various bioactive compounds due to its unique chemical structure and properties. It plays a crucial role in the development of new drugs targeting specific biological pathways.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Aminomethyl-4-(4-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is utilized as a starting material for the development of new drugs. Its potential pharmacological activities make it a promising candidate for creating innovative therapeutic agents that can address unmet medical needs.
Used in Drug Discovery and Development Research:
4-Aminomethyl-4-(4-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is employed as a valuable tool in drug discovery and development research. Its chemical properties and structure enable researchers to explore its potential in creating novel compounds with therapeutic benefits, ultimately contributing to advancements in the field of medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 847615-01-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,6,1 and 5 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 847615-01:
(8*8)+(7*4)+(6*7)+(5*6)+(4*1)+(3*5)+(2*0)+(1*1)=184
184 % 10 = 4
So 847615-01-4 is a valid CAS Registry Number.
847615-01-4Relevant academic research and scientific papers
2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
-
Page/Page column 19; 9, (2008/06/13)
The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
